Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free BTTX Stock Alerts

Better Therapeutics (BTTX) Competitors

Better Therapeutics logo
Compare

BTTX vs. UPHL, IMAC, VRAYQ, VRPX, and WINT

Should you buy Better Therapeutics stock or one of its competitors? Better Therapeutics's main competitors and comparable companies include UpHealth (UPHL), IMAC (IMAC), ViewRay (VRAYQ), Virpax Pharmaceuticals (VRPX), and Windtree Therapeutics (WINT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Better Therapeutics compare to UpHealth?

Better Therapeutics (NASDAQ:BTTX) and UpHealth (NYSE:UPHL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Better Therapeutics has higher earnings, but lower revenue than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
UpHealth$130M0.00-$56.42M$1.980.00

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
UpHealth N/A N/A N/A

Better Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, UpHealth has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
UpHealth Neutral

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 34.2% of UpHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

UpHealth beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Better Therapeutics compare to IMAC?

IMAC (NASDAQ:IMAC) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

In the previous week, IMAC had 6 more articles in the media than Better Therapeutics. MarketBeat recorded 6 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.60 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Positive
Better Therapeutics Neutral

24.3% of IMAC shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.00-$10.54M-$0.27N/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Better Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Better Therapeutics' return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
Better Therapeutics N/A N/A N/A

Summary

Better Therapeutics beats IMAC on 7 of the 12 factors compared between the two stocks.

How does Better Therapeutics compare to ViewRay?

ViewRay (NASDAQ:VRAYQ) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Comparatively, 51.4% of Better Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
ViewRayN/A N/A N/A
Better Therapeutics N/A N/A N/A

Better Therapeutics has lower revenue, but higher earnings than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ViewRay$102.21M0.00-$107.33MN/AN/A
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score.

Company Overall Sentiment
ViewRay Neutral
Better Therapeutics Neutral

ViewRay has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Summary

Better Therapeutics beats ViewRay on 5 of the 6 factors compared between the two stocks.

How does Better Therapeutics compare to Virpax Pharmaceuticals?

Better Therapeutics (NASDAQ:BTTX) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Better Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
Virpax Pharmaceuticals Neutral

Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.55, suggesting that its share price is 1,755% less volatile than the broader market.

Summary

Better Therapeutics beats Virpax Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

How does Better Therapeutics compare to Windtree Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Better Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

Windtree Therapeutics is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
Windtree Therapeutics Neutral

Better Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market.

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Better Therapeutics beats Windtree Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Better Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTTX vs. The Competition

Export
MetricBetter TherapeuticsHealth services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$3.14M$7.15B$13.26B
Dividend YieldN/AN/A2.53%17.36%
P/E Ratio0.00N/A274.3426.20
Price / SalesN/A0.00619.1192.00
Price / CashN/AN/A27.2234.70
Price / BookN/A0.0011.236.40
Net Income-$39.76M-$56.42M$3.49B$381.07M

Better Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTTX
Better Therapeutics
N/AN/AN/AN/A$4KN/AN/A40
UPHL
UpHealth
N/AN/AN/A-50.0%$2K$130MN/A374
IMAC
IMAC
N/A$0.00
flat		N/AN/A$16K$15.22MN/A106
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A295
VRPX
Virpax Pharmaceuticals
N/AN/AN/A+638.1%$14KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BTTX) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
They're not telling you how bad this could get
Valuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...
Parkview Capital Group | Sponsoredtc pixel
This smart glasses tech is bringing the screen to your eyes
Global AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...
The Tomorrow Investor | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Musk says UBI is coming. I say it's already here.
Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...
Freedom Financial | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel